Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study

G V Doern; A B Brueggemann; G Pierce; T Hogan; H P Holley; A Rauch

doi:10.1128/AAC.40.12.2884

Back

Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study

Journal article

Open access

Peer reviewed

Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study

G V Doern, A B Brueggemann, G Pierce, T Hogan, H P Holley and A Rauch

Antimicrobial agents and chemotherapy, Vol.40(12), pp.2884-2886

12/1996

DOI: 10.1128/AAC.40.12.2884

PMCID: PMC163641

PMID: 9124860

Files and links (1)

url

https://doi.org/10.1128/AAC.40.12.2884View

Published (Version of record) Open Access

Abstract

Seven hundred twenty-three isolates of Moraxella catarrhalis obtained from outpatients with a variety of infections in 30 medical centers in the United States between 1 November 1994 and 30 April 1995 were characterized in a central laboratory. The overall rate of beta-lactamase production was 95.3%. When the National Committee for Clinical Laboratory Standards MIC interpretive breakpoints for Haemophilus influenzae were applied, percentages of strains found to be susceptible to selected oral antimicrobial agents were as follows: azithromycin, clarithromycin, and erythromycin, 100%; tetracycline and chloramphenicol, 100%; amoxicillin-clavulanate, 100%; cefixime, 99.3%; cefpodoxime, 99.0%; cefaclor, 99.4%; loracarbef, 99.0%; cefuroxime, 98.5%; cefprozil, 94.3%; and trimethoprim-sulfamethoxazole, 93.5%.

Details

Title: Subtitle: Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study
Creators: G V Doern - Clinical Microbiology Laboratories, University of Massachusetts, Worcester 01655, USA
A B Brueggemann - Clinical Microbiology Laboratories, University of Massachusetts, Worcester 01655, USA
G Pierce - Clinical Microbiology Laboratories, University of Massachusetts, Worcester 01655, USA
T Hogan - Clinical Microbiology Laboratories, University of Massachusetts, Worcester 01655, USA
H P Holley - Clinical Microbiology Laboratories, University of Massachusetts, Worcester 01655, USA
A Rauch - Clinical Microbiology Laboratories, University of Massachusetts, Worcester 01655, USA
Resource Type: Journal article
Publication Details: Antimicrobial agents and chemotherapy, Vol.40(12), pp.2884-2886
DOI: 10.1128/AAC.40.12.2884
PMID: 9124860
PMCID: PMC163641
ISSN: 0066-4804
eISSN: 1098-6596
Language: English
Date published: 12/1996
Academic Unit: Epidemiology; Pathology; Health and Human Physiology; Internal Medicine
Record Identifier: 9984002332102771

Metrics

11 Record Views

89 Times Cited - Web of Science